ProShares Trust. Holdings as of May 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| N/ADerivative | 7.35% | $5.42M | 3,524 |
| ProShares GENIUS Money Market ETFOther | 6.80% | $5.01M | 50,000 |
| Gilead Sciences, Inc.GILD | 4.66% | $3.43M | 25,542 |
| Vertex Pharmaceuticals, Inc.VRTX | 4.65% | $3.43M | 7,657 |
| Amgen, Inc.AMGN | 4.48% | $3.30M | 9,803 |
| N/ADerivative | 3.94% | $2.90M | 2,513 |
| N/ADerivative | 3.26% | $2.40M | 2,639 |
| Regeneron Pharmaceuticals, Inc.REGN | 3.21% | $2.36M | 3,840 |
| N/ADerivative | 2.62% | $1.93M | 3,374 |
| Alnylam Pharmaceuticals, Inc.ALNY | 2.01% | $1.48M | 4,904 |
| Revolution Medicines, Inc.RVMD | 1.57% | $1.15M | 7,326 |
| Biogen, Inc.BIIB | 1.44% | $1.06M | 5,425 |
| Repurchase AgreementRA | 1.28% | $944.61K | 944,611 |
| Illumina, Inc.ILMN | 1.25% | $921.21K | 5,653 |
| United Therapeutics Corp.UTHR | 1.22% | $902.05K | 1,620 |
| Royalty Pharma plc | 1.20% | $883.07K | 15,837 |
| Argenx SEARGX | 1.19% | $877.79K | 1,050 |
| N/ADerivative | 1.18% | $871.18K | 4,232 |
| Insmed, Inc.INSM | 1.16% | $851.86K | 7,968 |
| Roivant Sciences Ltd. | 1.08% | $793.54K | 26,460 |
| Incyte Corp.INCY | 0.97% | $711.91K | 7,359 |
| Viatris, Inc.VTRS | 0.94% | $692.11K | 42,565 |
| Moderna, Inc.MRNA | 0.94% | $688.97K | 14,600 |
| Guardant Health, Inc.GH | 0.85% | $629.00K | 4,850 |
| INVESCO GOVT AND AGCY LEXCash or money market | 0.81% | $598.02K | 598,016 |
| Repurchase AgreementRA | 0.81% | $594.44K | 594,435 |
| Neurocrine Biosciences, Inc.NBIX | 0.80% | $587.61K | 3,712 |
| Jazz Pharmaceuticals plc | 0.73% | $538.01K | 2,275 |
| Ascendis Pharma A/S | 0.69% | $510.07K | 2,276 |
| Summit Therapeutics, Inc.SMMT | 0.68% | $502.77K | 28,664 |
| Exelixis, Inc.EXEL | 0.66% | $484.61K | 9,600 |
| Bridgebio Pharma, Inc.BBIO | 0.64% | $474.89K | 7,167 |
| Medpace Holdings, Inc.MEDP | 0.64% | $469.91K | 1,051 |
| Ionis Pharmaceuticals, Inc.IONS | 0.63% | $467.34K | 6,109 |
| Repurchase AgreementRA | 0.61% | $445.83K | 445,826 |
| Axsome Therapeutics, Inc.AXSM | 0.60% | $443.17K | 1,890 |
| Madrigal Pharmaceuticals, Inc.MDGL | 0.57% | $421.19K | 847 |
| BioMarin Pharmaceutical, Inc.BMRN | 0.55% | $407.33K | 7,110 |
| BioNTech SEBNTX | 0.55% | $404.24K | 4,213 |
| Arrowhead Pharmaceuticals, Inc.ARWR | 0.55% | $403.42K | 5,178 |
| Sanofi SASNY | 0.54% | $395.08K | 9,047 |
| Praxis Precision Medicines, Inc.PRAX | 0.49% | $360.12K | 1,029 |
| Cytokinetics, Inc.CYTK | 0.47% | $349.49K | 4,553 |
| BeOne Medicines Ltd.ONC | 0.46% | $340.03K | 1,181 |
| Krystal Biotech, Inc.KRYS | 0.45% | $333.75K | 1,080 |
| Repurchase AgreementRA | 0.44% | $326.94K | 326,939 |
| Tempus AI, Inc.TEM | 0.44% | $324.22K | 6,424 |
| Abivax SAABVX | 0.41% | $301.20K | 2,271 |
| Nuvalent, Inc. | 0.41% | $298.60K | 2,705 |
| Halozyme Therapeutics, Inc.HALO | 0.39% | $290.38K | 4,364 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.